 |
|
Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial
Keiji Hirai, Susumu Ookawara, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Yuichirou Ueda, Yoshio Kaku, Taro Hoshino, Honami Mori, Izumi Yoshida, Kenji Kubota, Yasuyoshi Yamaji, Tetsuro Takeda, Yoshikazu Nakamura, Kaoru Tabei, Yoshiyuki Morishita
Kidney Res Clin Pract. 2017;36(2):159-166. Published online 2017 Jun 30 DOI: https://doi.org/10.23876/j.krcp.2017.36.2.159
|
|
Citations to this article as recorded by
 Quantitative Comparison of the Clinical Efficacy of 6 Classes Drugs for IgA Nephropathy: A Model-Based Meta-Analysis of Drugs for Clinical Treatments
Jiesen Yu, Jieren Luo, Haoxiang Zhu, Zichao Sui, Hongxia Liu, Lujin Li, Qingshan Zheng
Frontiers in Immunology.2022;[Epub] CrossRef Immunosuppressive agents for treating IgA nephropathy
Patrizia Natale, Suetonia C Palmer, Marinella Ruospo, Valeria M Saglimbene, Jonathan C Craig, Mariacristina Vecchio, Joshua A Samuels, Donald A Molony, Francesco Paolo Schena, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials
Zheng Zhang, Yue Yang, Shi-min Jiang, Wen-ge Li
BMC Nephrology.2019;[Epub] CrossRef
|